Life Science Cares Launches in Switzerland
April 19, 2024 11:12 ET
|
Molecular Partners
ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their...
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024 11:12 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Publishes Invitation to Annual General Meeting 2024
March 26, 2024 09:26 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
March 14, 2024 16:00 ET
|
Molecular Partners
Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at...
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024 16:17 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024 16:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024 16:00 ET
|
Molecular Partners
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved...
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024 16:00 ET
|
Molecular Partners
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive...
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023 12:00 ET
|
Molecular Partners
Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported...